Soraprazan is primarily investigated for its potential use in treating gastric acid-related disorders. It functions as a potent proton pump inhibitor, effectively reducing the production of stomach acid. This makes it a candidate for managing conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Its rapid onset of action and prolonged duration of effect could offer advantages over existing therapies, particularly for patients requiring quick relief or those with severe acid hypersecretion. Additionally, its unique mechanism may benefit individuals who are unresponsive to conventional proton pump inhibitors. Research is ongoing to explore its broader therapeutic applications and efficacy in various clinical settings.